In a patient who underwent chemotherapy for lung cancer ten years ago and now presents with fever, night sweats, weight loss (B symptoms) and leukocytosis, what is the appropriate diagnostic workup and differential diagnosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnostic Workup for B Symptoms and Leukocytosis 10 Years Post-Lung Cancer Chemotherapy

In a patient presenting with B symptoms and leukocytosis 10 years after lung cancer chemotherapy, you must immediately pursue tissue diagnosis to differentiate between three critical possibilities: therapy-related acute myeloid leukemia (t-AML), recurrent/new lung malignancy with paraneoplastic leukocytosis, or lymphoma (particularly Hodgkin lymphoma). The 10-year interval makes therapy-related AML highly relevant, as these cases can occur years after cytotoxic chemotherapy exposure 1.

Immediate Diagnostic Priorities

1. Peripheral Blood Smear and Complete Blood Count with Differential

  • Examine for circulating blasts, which would indicate acute leukemia 1
  • Assess the degree and type of leukocytosis (neutrophilic vs. lymphocytic vs. blastic)
  • In t-AML cases, blast percentages can exceed 70% 1

2. Imaging Studies

  • CT chest with contrast to evaluate for:
    • New or recurrent lung masses
    • Mediastinal/hilar lymphadenopathy (suggests SCLC recurrence or lymphoma) 2
    • Pleural effusions requiring thoracentesis 2
  • PET/CT to identify metabolically active disease and guide biopsy site selection 3

3. Tissue Diagnosis - The Critical Step

If imaging shows accessible lesions, obtain tissue by the least invasive method 2:

  • For lymphadenopathy: Excisional lymph node biopsy is preferred over fine-needle aspiration to allow full architectural assessment and immunohistochemistry, which is essential to differentiate lymphoma from TB or sarcoidosis 4, 5

  • For pulmonary lesions:

    • Bronchoscopy with transbronchial biopsy if central
    • CT-guided needle biopsy if peripheral 2
    • Ensure adequate tissue for both histology AND molecular testing 3

  • For suspected hematologic malignancy:

    • Bone marrow aspiration and biopsy with:
      • Flow cytometry
      • Cytogenetics
      • Next-generation sequencing for DNMT3A, U2AF1, PPM1D mutations (characteristic of t-AML) 1
      • BCR-ABL and JAK2 mutation analysis to exclude chronic myeloid leukemia 6

Key Differential Diagnoses

Therapy-Related AML (Most Critical)

  • Occurs after prior chemotherapy exposure, even years later 1
  • Presents with cytopenias, circulating blasts, and can have extramedullary manifestations (leukemia cutis) 1
  • Poor prognosis with adverse-risk mutations 1
  • Definitive diagnosis requires bone marrow biopsy

Paraneoplastic Leukocytosis from Recurrent Lung Cancer

  • More common in non-small cell lung cancer, especially large cell carcinoma 7
  • Caused by tumor production of G-CSF, GM-CSF, or IL-6 8, 7
  • Leukocytosis can be extreme (>140,000/μL) without infection 6
  • Key distinguishing feature: Leukocytosis rapidly resolves with chemotherapy treatment of the underlying cancer 8
  • Serum procalcitonin remains normal despite leukocytosis 8
  • Poor prognostic sign when present 7

Hodgkin Lymphoma

  • Can coexist with or mimic tuberculosis 4
  • Presents with B symptoms and lymphadenopathy
  • Requires excisional biopsy with immunohistochemistry for definitive diagnosis 4

Infectious Causes (TB, Sarcoidosis)

  • TB can reactivate during immunosuppression and shares clinical features with lymphoma 4
  • Sarcoidosis can develop post-chemotherapy with fever and pulmonary nodules 5
  • Both require histopathological confirmation with non-caseating granulomas 5

Critical Pitfalls to Avoid

  1. Do not assume leukocytosis is infectious without tissue diagnosis - Empirical antibiotics may temporarily reduce fever but won't address underlying malignancy 8

  2. Do not rely on fine-needle aspiration alone for lymphadenopathy - Excisional biopsy is necessary for architectural assessment to differentiate lymphoma from granulomatous disease 4

  3. Do not delay bone marrow biopsy if peripheral smear shows blasts or unexplained cytopenias - t-AML requires urgent diagnosis 1

  4. Ensure adequate tissue for molecular testing - Modern lung cancer management requires EGFR, ALK, and ROS1 testing if recurrent NSCLC is diagnosed 3, 9

Algorithmic Approach

Step 1: Peripheral smear review

  • If blasts present → Immediate bone marrow biopsy for suspected t-AML 1
  • If mature leukocytosis → Proceed to Step 2

Step 2: CT chest and PET/CT

  • If accessible lymph nodes → Excisional biopsy 4
  • If pulmonary mass → Bronchoscopy or CT-guided biopsy 2
  • If pleural effusion → Thoracentesis with cytology 2

Step 3: Based on tissue diagnosis

  • t-AML confirmed → Hematology consultation, consider hospice vs. chemotherapy based on performance status and mutations 1
  • Recurrent lung cancer → Treat underlying malignancy; leukocytosis will resolve with effective chemotherapy 8
  • Lymphoma → Staging and appropriate chemotherapy regimen 4

The priority is obtaining definitive tissue diagnosis before initiating any treatment, as the therapeutic approach differs dramatically between these entities 2, 3, 1.

References

9
Research

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2026

Related Questions

What is the appropriate management for a 36-year-old woman with new marked leukocytosis (WBC 22.1 ×10⁹/L, absolute neutrophil count 17.0 ×10⁹/L), thrombocytosis (platelets 572 ×10⁹/L), mild hypokalemia (potassium 3.4 mmol/L), low bicarbonate (CO₂ 19 mmol/L), elevated alkaline phosphatase (159 U/L), dyslipidemia (LDL 143 mg/dL, HDL 39 mg/dL, total cholesterol 204 mg/dL), vitamin D insufficiency (24.4 ng/mL), and well‑controlled type 2 diabetes (A1c 5.3 %)?
In a 62-year-old man with a 20-year history of smoking three-quarters of a pack per day (~15 pack-years), is low-dose computed tomography (CT) screening for lung cancer indicated?
Can a contrast‑enhanced CT angiography performed one year ago replace an annual low‑dose CT scan for lung‑cancer screening in a 62‑year‑old man who quit smoking 10 years ago?
In a 72-year-old patient with a prior history of cytotoxic chemotherapy who now presents with lymphocytosis, what is the recommended evaluation and management?
In a 28-year-old patient with a family history of lung cancer, colorectal cancer, and an unspecified malignancy, are there indications for accelerated cancer screening?
What is the recommended perioperative warfarin-to-enoxaparin (Lovenox) bridging protocol for a patient undergoing surgery?
What does a markedly low anion gap of 3 mEq/L with an elevated bicarbonate (CO₂) of 36 mEq/L indicate, and what are the appropriate management steps?
In a newborn with perioral cyanosis and a systolic blood pressure gradient between the upper and lower extremities, what is the best next step in management?
In an 11-year-old female with nocturnal enuresis and microscopic hematuria (3–5 red blood cells per high-power field) on urinalysis, what further workup is indicated?
In children with nephrotic syndrome, can fresh frozen plasma be used as an alternative to albumin, together with furosemide, for edema control?
What second‑generation antihistamine is recommended for an elderly patient, and how should dosing be adjusted for renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.